Skip to Content

Sigilon Therapeutics Inc Ordinary Shares SGTX Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SGTX

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics SGTX

Company Profile SGTX

Business Description

Sigilon Therapeutics Inc is a clinical stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. Its lead product candidate, SIG-001, prevents bleeding in patients with moderate-severe to severe Hemophilia A.

100 Binney Street, Suite 600
Cambridge, MA, 02142
T +1 617 336-7540
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 99